Kiniksa Pharmaceuticals Stock Forecast, Price & News

-0.63 (-4.60 %)
(As of 08/4/2021 03:06 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume21,795 shs
Average Volume470,897 shs
Market Capitalization$891.08 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive KNSA News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Kiniksa Pharmaceuticals logo

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its product candidates include Rilonacept, which is in Phase III clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody that is in Phase II clinical trials for the treatment of giant cell arteritis; and Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40/CD40L interaction, a central control node of T-cell-dependent, and B-cell-mediated humoral adaptive immunity. The company has a clinical collaboration with Kite Pharma, Inc. to evaluate the combination of Yescarta and Mavrilimumab in patients with relapsed or refractory Large B-Cell lymphoma. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.18 out of 5 stars

Medical Sector

1012th out of 1,309 stocks

Pharmaceutical Preparations Industry

504th out of 646 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Kiniksa Pharmaceuticals (NASDAQ:KNSA) Frequently Asked Questions

Is Kiniksa Pharmaceuticals a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Kiniksa Pharmaceuticals stock.
View analyst ratings for Kiniksa Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Kiniksa Pharmaceuticals?

Wall Street analysts have given Kiniksa Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kiniksa Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Kiniksa Pharmaceuticals' next earnings date?

Kiniksa Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Kiniksa Pharmaceuticals

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) posted its earnings results on Tuesday, August, 3rd. The company reported ($0.61) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.69) by $0.08.
View Kiniksa Pharmaceuticals' earnings history

How has Kiniksa Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Kiniksa Pharmaceuticals' stock was trading at $16.10 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KNSA stock has decreased by 18.6% and is now trading at $13.11.
View which stocks have been most impacted by COVID-19

What price target have analysts set for KNSA?

2 equities research analysts have issued 1-year price objectives for Kiniksa Pharmaceuticals' stock. Their forecasts range from $24.00 to $24.00. On average, they expect Kiniksa Pharmaceuticals' share price to reach $24.00 in the next twelve months. This suggests a possible upside of 83.1% from the stock's current price.
View analysts' price targets for Kiniksa Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Kiniksa Pharmaceuticals' key executives?

Kiniksa Pharmaceuticals' management team includes the following people:
  • Mr. Sanj K. Patel, CEO & Chairman (Age 51, Pay $1.43M)
  • Mr. Mark Ragosa C.F.A., Sr. VP & CFO (Age 46)
  • Mr. Michael R. Megna, Chief Accounting Officer & VP of Fin. (Age 50)
  • Mr. Chad Morin, VP & Chief Compliance Officer
  • Ms. Madelyn Zeylikman, Gen. Counsel
  • Ms. Melissa Manno, Chief HR Officer
  • Dr. John F. Paolini, Sr. VP & Chief Medical Officer (Age 56)
  • Mr. Rasmus Holm-Jorgensen, Sr. VP, Chief Strategy & Portfolio Officer
  • Mr. Carsten Boess, Exec. VP of Corp. Affairs (Age 54)
  • Ms. Christine Maurer, Sr. VP of Program Management

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?

1 employees have rated Kiniksa Pharmaceuticals CEO Sanj K. Patel on Sanj K. Patel has an approval rating of 100% among Kiniksa Pharmaceuticals' employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Kiniksa Pharmaceuticals' key competitors?

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

When did Kiniksa Pharmaceuticals IPO?

(KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Kiniksa Pharmaceuticals' stock symbol?

Kiniksa Pharmaceuticals trades on the NASDAQ under the ticker symbol "KNSA."

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (1.08%), Alliancebernstein L.P. (0.05%), Vigilare Wealth Management (0.03%), Russell Investments Group Ltd. (0.02%) and Cutler Group LP (0.00%). Company insiders that own Kiniksa Pharmaceuticals stock include John F Paolini, Sanj K Patel and Thomas W Beetham.
View institutional ownership trends for Kiniksa Pharmaceuticals

Which institutional investors are selling Kiniksa Pharmaceuticals stock?

KNSA stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP, and Russell Investments Group Ltd.. Company insiders that have sold Kiniksa Pharmaceuticals company stock in the last year include Sanj K Patel, and Thomas W Beetham.
View insider buying and selling activity for Kiniksa Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Kiniksa Pharmaceuticals stock?

KNSA stock was purchased by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Alliancebernstein L.P., and Vigilare Wealth Management.
View insider buying and selling activity for Kiniksa Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kiniksa Pharmaceuticals' stock price today?

One share of KNSA stock can currently be purchased for approximately $13.11.

How much money does Kiniksa Pharmaceuticals make?

Kiniksa Pharmaceuticals has a market capitalization of $894.50 million. The company earns $-161,380,000.00 in net income (profit) each year or ($2.61) on an earnings per share basis.

How many employees does Kiniksa Pharmaceuticals have?

Kiniksa Pharmaceuticals employs 168 workers across the globe.

What is Kiniksa Pharmaceuticals' official website?

The official website for Kiniksa Pharmaceuticals is

Where are Kiniksa Pharmaceuticals' headquarters?

Kiniksa Pharmaceuticals is headquartered at CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11.

How can I contact Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals' mailing address is CLARENDON HOUSE 2 CHURCH STREET, HAMILTON D0, HM11. The company can be reached via phone at 44-80-8189-6257 or via email at [email protected]

This page was last updated on 8/4/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.